Abstract
Purpose :
Suprachoroidal triamcinolone acetonide suspension (Xipere TM) has been approved for the treatment of uveitis. This abstract examines the use of non-mydriatic optical coherence tomography (N-M OCT) as a biomarker for the efficacy of Xipere TM for treatment of uveitis.
Methods :
The drug inventory system of a large retinal practice was queried for the use of Xipere TM in 2023. Five cases were randomly selected, and the deidentified chart notes were reviewed for each patient’s age, sex, and lens status. This study was approved for a Waiver of Authorization from an Institutional Review Board. Each case was confirmed to have a diagnosis of posterior uveitis. The N-M OCTs were gathered before and after Xipere TM treatment. These results were reviewed by a masked grader, a retina specialist, familiar with the treatment of poster uveitis. Central subfield thickness (CST) was also quantified and recorded. Dates and number of Xipere TM administrations were tabulated.
Results :
Study participant ages ranged from 60 to 81 years old among 3 males and 2 females, 4 with pseudophakia and 1 with aphakia. All cases showed qualitative resolution of macular edema on N-M OCT per the masked physician. This was demonstrated within 4 to 6 weeks following Xipere TM treatment. CST pre-treatment thickness ranged from 346 to 504, and post treatment thickness ranged from 273 to 360.
Conclusions :
N-M OCT appears to be an accurate imaging modality as a biomarker to assess for the response of poster uveitis to Xipere TM treatment. Further studies may try to correlate the N-M OCTs changes to other biomarkers or exam findings such as cell count or flare.
This abstract was presented at the 2024 ARVO Imaging in the Eye Conference, held in Seattle, WA, May 4, 2024.